RCS - Physiomics PLC - Business Update Presentation

PhysiomicsAnnouncement

10/11/2023 15:15

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20231110:nRSJ1375Ta&default-theme=true

RNS Number : 1375T  Physiomics PLC  10 November 2023

10 November 2023

 

Physiomics plc

("Physiomics" or "the Company")

 

Business Update

 

Physiomics plc (AIM: PYC), is pleased to announce that, following today's
announcement of a significant grant award from Innovate UK and The Office for
Life Sciences to support the Company's personalised dosing programme, Dr Jim
Millen and Dr Pete Sargent will provide a business update via Investor Meet
Company on 17 November 2023 at 1:00 pm GMT.

 

The presentation is open to all existing and potential shareholders. Questions
can be submitted pre-event via your Investor Meet Company dashboard up until
9:00 am GMT the day before the meeting or at any time during the live
presentation.

 

Investors can sign up to Investor Meet Company for free and add to meet
Physiomicsplc via:

https://www.investormeetcompany.com/physiomics-plc/register-investor
(https://www.investormeetcompany.com/physiomics-plc/register-investor) .
Investors who already follow the Company on the Investor Meet Company platform
will automatically be invited.

 

 

Enquiries:

 

Physiomics plc

Dr Jim Millen, CEO

+44 (0)1865 784 980

 

Hybridan LLP (Broker)

Claire Louise Noyce

+44 (0) 203 764 2341

 

Strand Hanson Ltd (NOMAD)

James Dance & James Bellman

+44 (0)20 7409 3494

 

 

Notes to Editor

 

 

About Physiomics

 

Physiomics plc combines cutting edge PK/PD and QSP modelling techniques with
cancer biology expertise, to help biotech and pharma companies streamline
their drug development journeys.

 

Our approach is to derive insight from all relevant data in order to de-risk
decision making and optimise design of pre-clinical and clinical studies.

 

Through use of bespoke models and our proprietary Virtual Tumour technology,
the Physiomics team has informed the development of over 100 commercial
projects, over 50 targets and 75 drugs. Clients include Merck KGaA, Astellas,
Bicycle Therapeutics, Numab Therapeutics & CRUK.

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRANKKBDPBDDBDD